Relying on the existing level of medical technology is not possible to cure Parkinson’s disease, the therapeutic measures taken for the disease is only symptomatic treatment, the purpose is to control the clinical symptoms, reduce the pain, slow down the development of the disease, and improve the quality of life of patients. So far, there is no cure-all for Parkinson’s disease. However, patients are often induced by some medical advertisements, mistakenly believe that Parkinson’s disease can be cured with certain prescriptions and take the risk of believing in taking them, which not only delay the condition, but also aggravate their own financial burden, which is often more than worth the loss. At present, the treatment of Parkinson’s disease patients is mainly through long-term medication to control symptoms. Drugs for the treatment of Parkinson’s disease can be broadly divided into the following seven types: 1, dopa preparations: refers to levodopa and compound levodopa, the latter is mainly used at present, for example, Medopa, Xining, etc.; 2, dopamine agonists: such as bromocriptine, Tysudan, Kryptopar, Pramipexole, Lopinilol, Carmeglumine, Rortigotine; 3, anticholinergic drugs: antan, etc.; 4, B-type monoamine oxidase inhibitor: Silymarin (Silymarin, Silymarin, Silymarin, Silymarin, Silymarin, Silymarin, Silymarin, Silymarin). Gillan (Sigitinin, Midol, Ginspin), Rasagiline; 5, catechol-oxygen methyltransferase inhibitors (COMT): tolcapone (A is the United States), entocapone (Cotan); 6, amantadine; 7, neuroprotective agents: coenzyme Q10 and so on. Due to the different mechanisms of action of the above drugs, when and under what circumstances to use what drugs, dosage size, must be made by the neurologist according to different patients with different individualized prescription, under the guidance of the doctor to take. The use of medications in combination with rehabilitation exercises such as relaxation exercises, joint range of motion training, balance training, visual cueing exercises, etc. can effectively improve symptoms. After the middle and late stages of PD, many patients will inevitably experience serious complications such as diminished drug efficacy, fluctuating symptoms, and anisocoria, which cannot be resolved by the above mentioned medication adjustments in some of the patients, and at this time, appropriate surgical procedures will be a good choice. Microelectrode-guided modern stereotactic neurosurgery is a world-leading high-tech in the 1990s. Surgery has a significant effect on the symptoms of tremor, rigidity and motor retardation of Parkinson’s disease patients, and effectively overcomes the decline in the efficacy of levodopa drugs and the serious “on-off phenomenon” and choreography caused by the increasing dose of the drug, etc. DBS (Deep Brain Stimulation), also known as the brain pacemaker, is the use of stereotactic brain surgery to stimulate a certain part of the brain. DBS, deep brain stimulation, also known as a pacemaker, is a procedure that uses stereotactic brain surgery to implant electrodes in a specific location in the brain, such as the thalamic nucleus. such as the thalamic floor nucleus. Studies in several clinical centers have shown that DBS of the thalamic nucleus not only improves all the symptoms of PD, including midline symptoms such as “difficulty in starting” and “stiffness of step”, but also reduces the dosage of levodopa, and has adverse effects such as anisocoria. It also reduces the dosage of levodopa, and is effective against the adverse effects of levodopa, such as anisocoria and painful spasms. One study reported that DBS reduced total UPDRS scores by 42% and motor function scores by 48% during the “off” period of the drug. Tremor, rigidity and bradykinesia improved significantly. The total amount of medication was reduced by 38% at 1 year and 36% at 2 years postoperatively. There was a 46.4% reduction in isokinetic scores. The procedure is mainly indicated for patients with: 1. typical PD that had been effective on levodopa preparations. 2. After systemic medication, symptoms can no longer be controlled or comorbidities of dyskinesia develop, which cannot be improved by adjusting medication. 3, No severe cognitive and psychiatric disorders and severe brain atrophy. 4, after diagnosis of levodopa treatment for at least 5 years, the time limit is based on two points, one is because PD responds well to levodopa, and its “honeymoon period” is more than 5 years, if the patient responds poorly to levodopa at an early stage, the diagnosis of PD is doubtful; two is because some patients with PD superimposed syndrome, early symptoms are mild, and the response to levodopa is poor; two is because some patients with PD superimposed syndrome, early symptoms are mild, and the response to levodopa is poor. Second, it is because some patients with PD superimposed syndrome have mild symptoms in the early stage and also have a certain response to levodopa, at this time, if the surgery, not only has no therapeutic effect, but also may aggravate the condition. Surgery has a significant effect on tremor, rigidity and bradykinesia in Parkinson’s disease, with an overall effective rate of more than 98% and a symptom improvement rate of about 80%. The complication rate of surgery is about 1-2%. When you or your family members have Parkinson’s disease, please do not panic, early medical treatment, reasonable and regular treatment can slow down the progress of the disease, maximize the improvement of symptoms, improve the quality of life, reduce the burden on the family.